CN111751545A - 一种筛选pd-l1/pd-1检测点抑制剂的方法 - Google Patents
一种筛选pd-l1/pd-1检测点抑制剂的方法 Download PDFInfo
- Publication number
- CN111751545A CN111751545A CN201910245001.5A CN201910245001A CN111751545A CN 111751545 A CN111751545 A CN 111751545A CN 201910245001 A CN201910245001 A CN 201910245001A CN 111751545 A CN111751545 A CN 111751545A
- Authority
- CN
- China
- Prior art keywords
- culture system
- protein
- cells
- inhibitor
- checkpoint inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010074708 B7-H1 Antigen Proteins 0.000 title claims abstract description 147
- 102000008096 B7-H1 Antigen Human genes 0.000 title claims abstract description 147
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000012216 screening Methods 0.000 title claims abstract description 17
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims abstract description 15
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims abstract description 15
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims abstract description 119
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract description 118
- 238000003501 co-culture Methods 0.000 claims abstract description 24
- 230000013595 glycosylation Effects 0.000 claims abstract description 14
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000012360 testing method Methods 0.000 claims abstract description 10
- 239000003112 inhibitor Substances 0.000 claims description 12
- 238000001262 western blot Methods 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- ZBOYJODMIAUJHH-SANMLTNESA-N (2s)-1-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound C=1C(OC)=C(CN2[C@@H](CCCC2)C(O)=O)C(OC)=CC=1OCC(C=1C)=CC=CC=1C1=CC=CC=C1 ZBOYJODMIAUJHH-SANMLTNESA-N 0.000 claims description 3
- JEDPSOYOYVELLZ-UHFFFAOYSA-N COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O Chemical compound COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O JEDPSOYOYVELLZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 claims description 3
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 2
- 150000004633 phorbol derivatives Chemical class 0.000 claims description 2
- 239000002644 phorbol ester Substances 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 229940121672 Glycosylation inhibitor Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 15
- 239000012528 membrane Substances 0.000 abstract description 12
- 238000012546 transfer Methods 0.000 abstract description 11
- 230000003993 interaction Effects 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000035790 physiological processes and functions Effects 0.000 abstract description 2
- 230000003872 anastomosis Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 64
- 239000000243 solution Substances 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 238000005406 washing Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 8
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 239000006180 TBST buffer Substances 0.000 description 7
- 229960003677 chloroquine Drugs 0.000 description 7
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
- 229960001467 bortezomib Drugs 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- -1 small molecule compounds Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 239000012668 PD-1-inhibitor Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000006674 lysosomal degradation Effects 0.000 description 2
- 230000006655 lysosomal degradation pathway Effects 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000007319 proteasomal degradation pathway Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- YYYARFHFWYKNLF-UHFFFAOYSA-N 4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=C12 YYYARFHFWYKNLF-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150091609 CD274 gene Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101100519206 Homo sapiens PDCD1 gene Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150087384 PDCD1 gene Proteins 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供了一种筛选PD‑L1/PD‑1检测点抑制剂的方法。具体地,包括步骤:(a)提供一个表达PD‑1的细胞株和表达PD‑L1的细胞株的共培养体系;(b)分别在测试组和对照组中,向所述共培养体系中添加候选组合物,并观察所述测试组和对照组中PD‑1的表达量和/或PD‑L1的糖基化情况。本发明的优点在于吻合生理过程,操作简便,成本低,高效率,结果准确度高,且能直观地反映药物对PD‑L1/PD‑1蛋白相互作用或PD‑L1蛋白膜转移的影响。
Description
技术领域
本发明属于生物技术领域,具体涉及一种筛选PD-L1/PD-1检测点抑制剂的方法。
背景技术
“免疫逃逸”是肿瘤的一大特征。机体的免疫系统在肿瘤发生初期可通过识别和清除癌变细胞来降低肿瘤发生率。而肿瘤细胞可通过调整自身或肿瘤微环境的状态来实现免疫逃逸,规避免疫杀伤。免疫检测点在调控免疫应答、维持对自身抗原的免疫耐受过程中担任着重要的角色。上调免疫检测点抑制分子的表达,是肿瘤细胞规避免疫杀伤的一种常见机制。通过拮抗免疫检测点信号通路可有效地抑制肿瘤生长。免疫治疗正在成为肿瘤治疗的重要方法。
PD-1(Programmed cell death protein 1,又称CD279),是目前最受关注的免疫检测点受体之一。它是由PDCD1基因编码表达含288个氨基酸的I型跨膜蛋白,属于CD28/CTLA-4免疫球蛋白超级家族,主要表达在活化的成熟T细胞中。PD-L1(Programmed death-ligand 1,又称CD274,B7-H1),是由CD274基因编码表达的含290个氨基酸的免疫球蛋白样I型跨膜蛋白,是PD-1的主要配体,目前已发现过表达于多种恶性肿瘤细胞中,包括淋巴瘤、黑色素瘤、肺癌、乳腺癌、恶性胶质瘤、卵巢癌、肾癌和膀胱癌等。PD-L1与PD-1的结合可介导后者胞内域发生磷酸化,以此招募胞质中的SHP-2磷酸酶对邻近的TCR通路分子去磷酸化从而抑制TCR下游信号通路,最终导致T细胞功能衰竭(T cell exhaustion)。
自2013年起,靶向PD-L1/PD-1通路的药物研发逐渐成为肿瘤免疫治疗的热点,主要的策略是通过设计抗体阻断PD-L1与PD-1的结合,解除PD-1通路对T细胞的抑制。截止至2018年6月,已有5个PD-L1/PD-1抗体或FDA批准上市,它们在临床上取得了突破性的治疗效果,尤其是针对晚期或转移性癌症的治疗。但同时,抗体类药物本身存在许多限制,比如其局限于静脉注射的单一用药方式、免疫原性、弱组织渗透性、低稳定性和高成本等。因此,其它类型尤其是小分子药物的开发显得日趋重要。尽管在目前而言,小分子化合物的开发远远滞后于抗体类药物,但随着PD-L1/PD-1复合物结构的细节被揭露,开发可有效阻断PD-L1/PD-1相互作用的小分子抑制剂已成为可能。
与开发PD-L1/PD-1抑制剂的巨大需求相对应的是目前尚不健全的筛选方法。目前已有多种结构的小分子化合物出现在已发表的专利或文献中,但鲜少有进一步的报道。它们在临床前研究中的失败大部分归咎于所使用的筛选方法。它们大多数都是基于检测体外的同源蛋白结合的筛选原理,比如最常用的 HTRF法(结合时间分辨荧光分析法(TRF,time-resolved fluoroimmunoassay) 和荧光能量共振转移(FRET)的一种方法)和体外蛋白竞争实验,这些体外检测方法虽然具备极高的敏感性,但与生理状况相去甚远,容易得到假阳性的结果;另外,通过检测T细胞效应功能(如ELIZA检测IFN-γ水平或CFSE法检测T细胞扩增)来筛选也是常见的手段,但影响T细胞效应改变的机理复杂多样,这些方法并不能直观地反映药物对PD-L1/PD-1检测点的影响。
由此可见,如何能更有效、准确地评估候选抗体或化合物针对PD-L1/PD-1 相互作用的方法,成为一个亟待解决的问题。
因此,本领域迫切需要开发一种便捷、有效、准确地筛选PD-L1/PD-1检测点抑制剂的方法。
发明内容
本发明的目的就是提供一种便捷、有效、准确地评估候选药物抑制 PD-L1/PD-1相互作用和信号转导的药物筛选和评价体系。
在本发明的第一方面,提供了一种筛选PD-L1/PD-1检测点抑制剂的候选组合物的方法,包括步骤:
(a)提供一培养体系,所述培养体系为表达PD-1的细胞株和表达PD-L1的细胞株的共培养体系;
(b)在测试组中,向所述培养体系中添加候选组合物,并观察所述测试组PD-1 的表达量和/或PD-L1的糖基化情况;在对照组中,在相同培养体系中不添加所述的候选组合物,并观察所述对照组中PD-1的表达量和/或PD-L1的糖基化情况;
其中,如果测试组培养体系中PD-1的表达量P1a显著高于对照组P0a,则说明所述候选组合物为PD-L1/PD-1检测点抑制剂;
如果测试组培养体系中PD-L1的糖基化情况改变,则说明所述候选组合物为 PD-L1/PD-1检测点。
在另一优选例中,所述PD-L1/PD-1检测点抑制剂为膜转移抑制剂。
在另一优选例中,所述表达PD-1的细胞株包括:Jurkat/PD-1、经细胞因子(IL-2等)、离子霉素联合佛波酯或抗CD3抗体联合抗CD28抗体刺激后上调PD-1的Jurkat 细胞、MOLT-4和RPMI-8226。
在另一优选例中,所述表达PD-L1的细胞株包括:PC-9/PD-L1、H1975、H460、H2228、Hcc827、MDA-MB-231、A2058、A375、SK-MEL-5、NCI-H226、EBC-1、 HDLM-2、U-251MG、U-138MG、CAPAN-2、TIME、SK-BR-3和A431。
在另一优选例中,所述培养体系为Jurkat/PD-1与PC-9/PD-L1的共培养体系。
在另一优选例中,所述“显著高于”指P1a/P0a的比值大于1,较佳地≥2,更佳地≥4。
在另一优选例中,所述PD-L1的糖基化情况包括PD-L1蛋白的western blot条带分布的改变。
在另一优选例中,所述PD-L1的糖基化情况包括55kD的PD-L1蛋白水平下降。
在另一优选例中,所述PD-L1的糖基化情况包括43kD的PD-L1蛋白水平增加。
在另一优选例中,所述PD-1来源于哺乳动物;优选地,来源于人、小鼠、大鼠、或兔;更优选地,来源于人。
在另一优选例中,所述PD-1包括PD-1的蛋白、编码核酸、活性片段或其衍生物。
在另一优选例中,所述PD-L1/PD-1检测点抑制剂包括PD-1抗体、或PD-L1/PD-1 的活性抑制剂。
在另一优选例中,所述PD-L1/PD-1检测点抑制剂选自下组:购自Selleck公司的两个小分子化合物(PD-1/PD-L1inhibitor 1和BMS-202)和一个环肽类抑制剂 (PD-1/PD-L1inhibitor 3)及其结构类似物。
在另一优选例中,所述PD-L1/PD-1检测点抑制剂抑制PD-1的溶酶体降解,表现为PD-1的表达量增加。
在另一优选例中,所述PD-L1的抑制剂选自下组:Bristol-Myers Squibb开发的化合物no.1166(US 2015/0291549A1)及其结构类似物。
在另一优选例中,所述方法是非诊断性和非治疗性方法。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例) 中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
附图说明
图1A用Western blot方法检测表明与野生型(WT)细胞相比,PC-9/PD-L1 细胞高表达PD-L1,其中GAPDH为内参;图1B用免疫荧光方法检测PD-L1的细胞定位情况,表明PC-9/PD-L1细胞中高表达的PD-L1定位在细胞膜上。
图2A用Western blot方法检测表明与野生型(WT)细胞相比,Jurkat/PD-1 细胞高表达PD-1,其中GAPDH为内参;图2B用流式细胞仪检测细胞表面PD-1 表达情况,表明Jurkat/PD-1细胞中高表达的PD-1定位在细胞膜上。NC为无抗体阴性对照,Alexa 488PD-1Ab为耦合Alexa 488基团的可识别PD-1的抗体。
图3检测了PC-9/PD-L1与Jurkat/PD-1细胞共培养所示时间后PD-L1和PD-1 的表达水平,显示PD-L1和PD-1的蛋白水平与共培养时间负相关。其中以GAPDH 或α-Tubulin为内参。下方的折线图为扫描灰度后经内参标准化的定量结果。
图4A在PC-9/PD-L1与Jurkat/PD-1细胞共培养的同时加入氯喹(CQ,chloroquine)或硼替佐米(BTZ,bortezomib)来分别抑制溶酶体降解通路或蛋白酶体降解通路,结果显示CQ可抑制共培养24小时后引起的PD-1降解,表明共培养促进了PD-1蛋白通过溶酶体降解;图4B在PC-9/PD-L1细胞中用Lipo 2000转染 negative control或PD-L1干扰RNA(PD-L1WT或PD-L1KD)处理24小时后与 Jurkat/PD-1共培养,结果表明下调PD-L1可稳定PD-1的表达;图4C中PC-9/PD-L1 细胞用PD-L1Ab或空白溶剂预处理1小时,再加入Jurkat/PD-1细胞共培养所示时间,结果显示PD-L1Ab可显著减少共培养24小时后PD-1的下调。图4B和C中下方柱状图为三次重复实验的定量结果。
图5A分别用所示浓度PD-L1Ab预处理PC-9/PD-L1细胞1小时,再与 Jurkat/PD-1细胞共培养0或17小时,结果表明PD-1水平可随PD-L1Ab浓度增加而增加;图5B中PC-9/PD-L1细胞分别用所示浓度化合物预处理1小时,再加入 Jurkat/PD-1细胞共培养所示时间,结果显示三种抑制剂都可以显著上调PD-1的表达水平。
图6在PC-9/PD-L1细胞中用Lipo 2000转染negative control或PD-L1干扰 RNA(PD-L1WT或PD-L1KD)处理24小时后检测PD-L1蛋白水平,以GAPDH 为内参。
图7中用所示浓度的no.1166化合物处理PC-9/PD-L1细胞过夜(A)或用10μ Mno.1166处理PC-9/PD-L1细胞所示时间(B),结果显示no.1166可改变PD-L1 蛋白的Westernblot条带分布。
图8A中PC-9/PD-L1细胞经DMSO(NC)或10μM no.1166处理过夜后被裂解,其中部分细胞裂解液作为input,余下部分与结合刀豆凝集素的琼脂糖(Agarose bound ConA)混悬过夜,结果表明与55kD左右的PD-L1相比,43kD左右的PD-L1 更易与刀豆凝集素结合,表明43kD PD-L1可能是高甘露糖型的糖蛋白;图8B中 PC-9/PD-L1细胞经DMSO(NC)或10μMno.1166处理过夜,收集细胞裂解液同 Endo H培养1小时,结果显示与55kD左右的PD-L1相比,43kD左右的PD-L1 不耐受Endo H,说明43kD PD-L1属于分泌晚期的产物;图8C用免疫荧光方法检测PD-L1(Green)与内质网(ER-tracker Red)的共定位情况,结果显示43kD PD-L1分布在内质网中,而55kD PD-L1分布在细胞膜上。
图9中PC-9/PD-L1细胞预先被所示浓度的PD-L1Ab或no.1166处理1小时,然后加入Jurkat/PD-1共培养17小时,检测PD-1水平表明no.1166上调PD-1的水平与PD-L1Ab相当,表明两者抑制PD-L1/PD-1相互作用能力相当。其中只有 no.1166会影响PD-L1条带分布。
具体实施方式
本发明人经过广泛而深入的研究,首次开发了一种便捷、有效、准确地评估候选药物抑制PD-L1和PD-1相互作用和信号转导的药物筛选和评价体系。该筛选体系由两种人工构建的细胞株组成——PC-9/PD-L1和Jurkat/PD-1。此两种细胞在体外的共培养造成PD-L1和PD-1的相互作用并导致PD-1蛋白降解。药物干扰能抑制PD-1蛋白的降解,经候选药物处理后共培养体系中PD-1的表达水平可以表征该药物对PD-L1/PD-1检测点的阻断程度。另一方面,由于 PD-L1的糖蛋白性质,作用于PD-L1的候选药物也会影响PD-L1的糖基化修饰从而改变PD-L1蛋白在Western blot上的分布模式。因此在PC-9/PD-L1细胞中,PD-L1蛋白在Western blot上条带的改变可以用来表征化合物对PD-L1蛋白膜转移的影响。在此基础上完成了本发明。
本发明的主要优点包括:
1)本发明所述的共培养筛选方法与现有的体外筛选方法(如均相时间分辨荧光技术和体外蛋白竞争实验)比较,更符合生理过程;与检测T细胞效应的方法相比,导致T细胞效应改变的机理复杂多样,阻断PD-L1/PD-1结合只是其中之一,通过共培养方法检测PD-1表达能更直观地反映药物对两蛋白相互作用的影响,而PC-9/PD-L1细胞的PD-L1糖基化可直观反映PD-L1蛋白的膜转移的影响。
2)本发明具有操作简便,成本低,高效率,结果准确度高的特点。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,例如Sambrook等人,分子克隆:实验室手册(New York:Cold Spring HarborLaboratory Press,1989)中所述的条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数是重量百分比和重量份数。
通用材料
1.药品与试剂
2.细胞与细胞培养基
细胞株均置于37℃含5%CO2的培养箱中培养,待细胞传至3-8代,处于对数生长期时进行实验。
通用方法
1.免疫印迹法(Western blot)分析
A.收集蛋白。加入1×sample buffer裂解细胞,收集细胞裂解液,100℃加热煮沸7-10min,使蛋白充分变性;
B.分离蛋白。12%-8%SDS-聚丙烯酰胺(SDS-PAGE)凝胶电泳分离蛋白(Tris-甘氨酸电泳液由Tris 3.02g,Glycine 18.8g和SDS 1g定容至1L)。浓缩胶电压维持80v,分离胶电压为120-140v;
C.半干法转膜。将分离的蛋白从胶中转移至硝酸纤维素膜上(转膜液由 Glycine2.9g,Tris 5.8g和SDS 0.37g溶于800ml去离子水中,使用前加入200 ml甲醇),转膜电压为9V,转膜时间视蛋白大小而定(34-55kD PD-L1和PD-1 蛋白转膜时间为25min);
D.丽春红染色。丽春红(丽春红4g,三氯乙酸60g,磺基水杨酸60g,加水定容至2L)染色5-7min后观察转膜效果;
E.牛奶封闭。5%脱脂奶粉TBST(Tris 2.42g,氯化钠8g,加水定容至1 L,调节pH为7.5,使用前加入1ml Tween 20)溶液覆盖蛋白条带于垂直摇床室温孵育1h;
F.一抗孵育。在5%牛血清白蛋白(BSA)TBST溶液中按1:1000-1:4000 比例稀释相应抗体,一抗溶液覆盖蛋白条带于垂直摇床室温孵育1h,再移至4 ℃孵育过夜,第二日于室温孵育1h后去除一抗溶液,加入TBST溶液放置于水平摇床洗10min,更换新的TBST溶液重复两遍;
G.二抗孵育。在5%牛血清白蛋白(BSA)TBST溶液中按1:5000比例稀释相应抗体,二抗溶液覆盖蛋白条带于垂直摇床室温孵育1h,去除上清加入TBST溶液放置于水平摇床洗10min,更换新的TBST溶液重复两遍;
H.化学发光显影。将化学发光底物(Millipore)按1:1混合,孵育在蛋白膜上,2-3min后在AZURE c300中显影拍照。
2.免疫荧光检测蛋白定位
A.细胞爬片。24孔板中放入免洗盖玻片,50,000-80,000细胞点板至~50%密度;
B.固定。移除上清,PBS溶液(氯化钠8g,氯化钾0.2g,十二水磷酸氢二钠3.49g,磷酸二氢钾0.2g,加水定容至1L,pH 7.4)洗三遍;4%多聚甲醛(PFA)溶液(PFA 40g/L,加入相应体积所需PBS所需的化合物,加入超纯水至80%,温育使PFA溶解,待溶液冷却后加入氢氧化钠调pH为7.0,定容)按300μl/孔加入,室温固定15min,PBS洗两遍,每遍5min;
C.打孔(如只检测细胞表面的PD-L1等蛋白表达,省去这一步)。0.1% Triton X-100PBS溶液室温孵育15min,PBS洗两遍,每遍5min;
D.封闭。0.1%PBST溶液(PBS+0.1%Tween 20)+10%马血清封闭液37 ℃孵育30min,
E.一抗孵育。将封闭后的盖玻片转移至疏水板中,在封闭液中按1:200比例稀释相应抗体,每盖玻片加上50μl一抗溶液,4℃孵育过夜,PBST溶液洗三遍;
F.二抗孵育。在封闭液中按1:1000比例稀释相应的荧光二抗,37℃孵育 1.5h,PBST溶液洗三遍;
G.细胞核染色。DAPI溶液(1:1000稀释与PBS中,0.1g/ml),300μl/ 孔,室温孵育10min,PBST溶液洗三遍;
H.封片。盖玻片反扣在滴有DAKO抗淬灭剂的载玻片上,注意赶走大的气泡;
I.激光共聚焦显微镜拍照。Olympus FLUOVIEW FV1000激光共聚焦显微镜在60×(1.42NA)PLAPON物镜(油镜)下拍照,FV10-ASW软件处理图片。
3.流式细胞仪检测Jurkat细胞表面PD-1表达
A.将孔内细胞(6孔板,100万细胞/孔)移至离心管中离心,500g×5min,弃上清,加入PBS枪头吹打数下洗一遍;
B.封闭。10%马血清PBS溶液封闭15min,200μl/管;
C.抗体孵育。AlexaFluor 488anti-human PD-1直接加入管中孵育30min, 2μl/管;
D.加入500μl PBST溶液,离心,弃上清;
E.加入500μl PBS溶液,离心,弃上清,最后加入500μl PBS;
F.流式细胞仪检测FL1-H通道。
4.共培养系统筛选PD-L1抑制剂
A.PC-9/PD-L1细胞点板贴壁,90%密度为宜;
B.加药预先处理PC-9/PD-L1细胞1h后,按PC-9/PD-L1的4倍数目加入 Jurkat/PD-1细胞进行共培养;
C.17-24h后,收集细胞裂解液。
5.RNA干扰实验
A.细胞点板贴壁,待密度达到30%-50%进行下一步骤;
B.按产品说明书在无血清培养基中稀释lipofectamine 2000,枪头吹打数下,室温静置5min;
C.在同样体积的无血清培养基中稀释RNA,枪头吹打数下;
D.将B和C混匀,室温静置20min;
E.孔内细胞换用无血清培养基培养,将D中混合物加到孔内;
F.24h后进入下一处理。
实验中所用siRNA(5’至3’)由上海吉玛制药技术有限公司合成,序列如下:
阴性对照:正义链-UUC UCC GAA CGU GUC ACG UTT(SEQ ID No.:1);反义链-ACGUGA CAC GUU CGG AGA ATT(SEQ ID No.:2);
PD-L1(人):正义链-GAG GAA GAC CUG AAG GUU CAG CAU A(SEQ ID No.:3);反义链-UAU GCU GAA CCU UCA GGU CUU CCU C(SEQ ID No.: 4);
PD-L1no.2(人):正义链-CCU ACU GGC AUU UGC UGA ACG CAU U (SEQ ID No.:5);反义链-AAU GCG UUC AGC AAA UGC CAG UAG G(SEQ ID No.:6);
PD-L1no.3(人):正义链-UGA UAC ACA UUU GGA GGA GAC GUA A (SEQ ID No.:7);反义链-UUA CGU CUC CUC CAA AUG UGU AUC A(SEQ ID No.:8)。
6.Endo H酶消化实验
取已用1×sample buffer收集的蛋白样品10μl,按照产品说明书加入2μl 10×GlycoBuffer 3,2μl Endo H,6μl水,37℃温育1h。
7.ER-tracker red染色
细胞加药处理后,移除培养基,加入ER-tracker工作液(ER-tracker red: 稀释液=1:1000-3000)300μl/孔,37℃孵育15-30min后移除,培养基洗涤1-2 次,预冷的PBS快速洗一遍,4%PFA室温避光固定。
实施例1.
本发明筛选体系由两种人工构建的细胞株组成:PC-9/PD-L1和 Jurkat/PD-1,PC-9/PD-L1为转染并高表达人PD-L1的人肺腺癌稳转细胞株(图 1);Jurkat/PD-1是转染并高表达人PD-1的白血病T细胞稳转细胞株(图2)。
将Jurkat/PD-1与PC-9/PD-L1细胞进行共培养以模拟T细胞浸润肿瘤组织的行为,可以发现随着共培养时间的延长,PD-1和PD-L1的蛋白量呈现时间依赖性减少的趋势,在共培养12-24小时后蛋白量明显降低,其中PD-1的变化尤为显著,如图3所示。
在PC-9/PD-L1与Jurkat/PD-1细胞共培养的同时加入氯喹(CQ, chloroquine)或硼替佐米(BTZ,bortezomib)来分别抑制溶酶体降解通路或蛋白酶体降解通路,结果如图4A所示,CQ可抑制共培养24小时后引起的PD-1 降解,表明共培养促进了PD-1蛋白通过溶酶体降解。在PC-9/PD-L1细胞中用 Lipo 2000转染negative control或PD-L1干扰RNA(PD-L1WT或PD-L1KD) 处理24小时后与Jurkat/PD-1共培养,结果如图4B所示,表明下调PD-L1可稳定PD-1的表达。PC-9/PD-L1细胞用PD-L1Ab或空白溶剂预处理1小时,再加入Jurkat/PD-1细胞共培养所示时间,结果如图4C所示,PD-L1Ab可显著减少共培养24小时后PD-1的下调。结果表明,通过RNA干扰的手段降低肿瘤细胞中PD-L1的表达,或使用阻断性抗体(PD-L1Ab)削弱PD-L1/PD-1相互作用都可以阻止PD-1的降解。
分别用所示浓度PD-L1Ab预处理PC-9/PD-L1细胞1小时,再与Jurkat/PD-1 细胞共培养0或17小时,结果如图5A所示,表明在PC-9/PD-L1和Jurkat/PD-1 的共培养体系中,PD-L1抗体可以随浓度增加逐步增加PD-1的蛋白水平; PC-9/PD-L1细胞分别用Selleck公司三种已商业化的PD-L1/PD-1抑制剂——两个小分子化合物(PD-1/PD-L1inhibitor 1和BMS-202)和一个环肽类抑制剂 (PD-1/PD-L1inhibitor 3)预处理1小时,再加入Jurkat/PD-1细胞共培养所示时间,结果如图5B所示,三种抑制剂都可以显著上调PD-1的表达水平。因此,通过检测经候选药物处理后共培养体系中PD-1的表达水平高低可以表征该药物对PD-L1/PD-1检测点的阻断程度。
在PC-9/PD-L1细胞中用Lipo 2000转染negative control或PD-L1干扰RNA (PD-L1WT或PD-L1KD)处理24小时后检测PD-L1蛋白水平,以GAPDH 为内参,由于PD-L1属于I型膜整合糖蛋白,已知在其N35、N192、N200和 N219四个天冬酰胺残基位点上存在大量N连接-糖基化修饰,而这样的糖基化修饰使得PD-L1蛋白在检测结果上呈现出多个非均匀的条带。结果如图6所示, PC-9/PD-L1细胞株中PD-L1蛋白在43-55kD间存在多个特异性条带。
用不同浓度的no.1166化合物处理PC-9/PD-L1细胞过夜或用10μM no.1166处理PC-9/PD-L1细胞不同时间,结果如图7所示,no.1166可改变PD-L1 蛋白的Western blot条带分布。N连接-糖基化是一种蛋白翻译后修饰。它是跨膜糖蛋白成熟的一个关键步骤,起始于内质网腔中多肽链的合成过程,随后在内质网-高尔基体分泌通路中被不同酶类进一步切割、加工为高甘露糖型、杂合型或复合型等不同结构。根据蛋白连接的糖型可以推断蛋白合成后的分泌阶段。在PC-9/PD-L1细胞中,PD-L1蛋白的Western blot条带分布可以反映PD-L1 蛋白的状态。由Bristol-Myers Squibb开发的化合物no.1166(US 2015/0291549A1)可随浓度和时间依赖性地促进55kD左右的PD-L1蛋白水平下降和43kD左右的蛋白增加。
本发明证实43kD左右的PD-L1为高甘露糖型的糖蛋白,可被糖苷内切酶 H(EndoH)消化,属于合成-分泌早期的糖蛋白,主要分布在内质网中;而55kD 左右的PD-L1为连接复合型聚糖的糖蛋白,可耐受Endo H,属于成熟糖蛋白,主要分布在细胞膜上(图8A-C)。
因此,通过候选药物对PD-L1蛋白的Western blot条带的改变可以表征其对PD-L1蛋白膜转移的影响。而PD-L1蛋白膜转移被抑制则必然会阻断 PD-L1/PD-1的相互作用和信号转导。该结果可以通过上述共培养体系验证,如图9所示。
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
序列表
<110> 中国科学院上海药物研究所
<120> 一种筛选PD-L1/PD-1检测点抑制剂的方法
<130> P2019-0138
<160> 8
<170> PatentIn version 3.5
<210> 1
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<220>
<221> misc_feature
<222> (20)..(21)
<223> n=T
<400> 1
uucuccgaac gugucacgun n 21
<210> 2
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<220>
<221> misc_feature
<222> (20)..(21)
<223> n=T
<400> 2
acgugacacg uucggagaan n 21
<210> 3
<211> 25
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 3
gaggaagacc ugaagguuca gcaua 25
<210> 4
<211> 25
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 4
uaugcugaac cuucaggucu uccuc 25
<210> 5
<211> 25
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 5
ccuacuggca uuugcugaac gcauu 25
<210> 6
<211> 25
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 6
aaugcguuca gcaaaugcca guagg 25
<210> 7
<211> 25
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 7
ugauacacau uuggaggaga cguaa 25
<210> 8
<211> 25
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 8
uuacgucucc uccaaaugug uauca 25
Claims (10)
1.一种筛选PD-L1/PD-1检测点抑制剂的候选组合物的方法,其特征在于,包括步骤:
(a)提供一培养体系,所述培养体系为表达PD-1的细胞株和表达PD-L1的细胞株的共培养体系;
(b)在测试组中,向所述培养体系中添加候选组合物,并观察所述测试组PD-1的表达量和/或PD-L1的糖基化情况;在对照组中,在相同培养体系中不添加所述的候选组合物,并观察所述对照组中PD-1的表达量和/或PD-L1的糖基化情况;
其中,如果测试组培养体系中PD-1的表达量P1a显著高于对照组P0a,则说明所述候选组合物为PD-L1/PD-1检测点抑制剂;
如果测试组培养体系中PD-L1的糖基化情况改变,则说明所述候选组合物为PD-L1/PD-1检测点。
2.如权利要求1所述的方法,其特征在于,所述PD-L1/PD-1检测点抑制剂为PD-L1糖基化抑制剂。
3.如权利要求1所述的方法,其特征在于,所述表达PD-1的细胞株包括:Jurkat/PD-1、经细胞因子、离子霉素联合佛波酯或抗CD3抗体联合抗CD28抗体刺激后上调PD-1的Jurkat细胞、MOLT-4和RPMI-8226。
4.如权利要求1所述的方法,其特征在于,所述表达PD-L1的细胞株包括:PC-9/PD-L1、H1975、H460、H2228、Hcc827、MDA-MB-231、A2058、A375、SK-MEL-5、NCI-H226、EBC-1、HDLM-2、U-251MG、U-138MG、CAPAN-2、TIME、SK-BR-3和A431。
5.如权利要求1所述的方法,其特征在于,所述培养体系为Jurkat/PD-1与PC-9/PD-L1的共培养体系。
6.如权利要求1所述的方法,其特征在于,在另一优选例中,所述“显著高于”指P1a/P0a的比值大于1。
7.如权利要求1所述的方法,其特征在于,所述PD-L1的糖基化情况包括PD-L1蛋白的western blot条带分布的改变。
8.如权利要求1所述的方法,其特征在于,所述PD-L1/PD-1检测点抑制剂包括PD-1抗体、或PD-L1/PD-1的活性抑制剂。
9.如权利要求1所述的方法,其特征在于,所述PD-L1/PD-1检测点抑制剂选自下组:PD-1/PD-L1 inhibitor 1、BMS-202、PD-1/PD-L1 inhibitor 3及其结构类似物。
10.如权利要求1所述的方法,其特征在于,所述PD-L1的抑制剂选自下组:化合物no.1166及其结构类似物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910245001.5A CN111751545A (zh) | 2019-03-28 | 2019-03-28 | 一种筛选pd-l1/pd-1检测点抑制剂的方法 |
PCT/CN2020/081787 WO2020192770A1 (zh) | 2019-03-28 | 2020-03-27 | 一种筛选pd-l1/pd-1检测点抑制剂的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910245001.5A CN111751545A (zh) | 2019-03-28 | 2019-03-28 | 一种筛选pd-l1/pd-1检测点抑制剂的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111751545A true CN111751545A (zh) | 2020-10-09 |
Family
ID=72611098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910245001.5A Pending CN111751545A (zh) | 2019-03-28 | 2019-03-28 | 一种筛选pd-l1/pd-1检测点抑制剂的方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111751545A (zh) |
WO (1) | WO2020192770A1 (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104711292A (zh) * | 2013-12-11 | 2015-06-17 | 深圳先进技术研究院 | 膜表达人pd-1蛋白的稳转株细胞构建方法 |
CN105828834A (zh) * | 2013-11-05 | 2016-08-03 | 同源生物服务股份有限公司 | 检查点抑制剂和治疗剂的组合以治疗癌症 |
WO2016146035A1 (en) * | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
CN107106608A (zh) * | 2014-11-20 | 2017-08-29 | 普洛麦格公司 | 用于评估免疫检查点调节剂的系统和方法 |
WO2017172517A1 (en) * | 2016-03-29 | 2017-10-05 | Stcube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
WO2018028449A1 (en) * | 2016-08-08 | 2018-02-15 | Beigene, Ltd. | Method for predicting efficacy of immune checkpoint inhibitors in cancer patients |
CN108780089A (zh) * | 2016-03-15 | 2018-11-09 | 美国控股实验室公司 | 评估细胞间的蛋白质相互作用的方法 |
CN109432429A (zh) * | 2018-12-29 | 2019-03-08 | 博生吉医药科技(苏州)有限公司 | Pd1分子抑制剂在t淋巴细胞白血病治疗中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108060132A (zh) * | 2016-11-09 | 2018-05-22 | 复旦大学 | 一种基于肿瘤细胞与肿瘤相关成纤维细胞的3d共培养模型 |
CN106955352A (zh) * | 2017-03-27 | 2017-07-18 | 顺昊细胞生物技术(天津)股份有限公司 | 一种用于治疗癌症的药物组合物和试剂盒 |
-
2019
- 2019-03-28 CN CN201910245001.5A patent/CN111751545A/zh active Pending
-
2020
- 2020-03-27 WO PCT/CN2020/081787 patent/WO2020192770A1/zh active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105828834A (zh) * | 2013-11-05 | 2016-08-03 | 同源生物服务股份有限公司 | 检查点抑制剂和治疗剂的组合以治疗癌症 |
CN104711292A (zh) * | 2013-12-11 | 2015-06-17 | 深圳先进技术研究院 | 膜表达人pd-1蛋白的稳转株细胞构建方法 |
CN107106608A (zh) * | 2014-11-20 | 2017-08-29 | 普洛麦格公司 | 用于评估免疫检查点调节剂的系统和方法 |
WO2016146035A1 (en) * | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
CN108780089A (zh) * | 2016-03-15 | 2018-11-09 | 美国控股实验室公司 | 评估细胞间的蛋白质相互作用的方法 |
WO2017172517A1 (en) * | 2016-03-29 | 2017-10-05 | Stcube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
WO2018028449A1 (en) * | 2016-08-08 | 2018-02-15 | Beigene, Ltd. | Method for predicting efficacy of immune checkpoint inhibitors in cancer patients |
CN109432429A (zh) * | 2018-12-29 | 2019-03-08 | 博生吉医药科技(苏州)有限公司 | Pd1分子抑制剂在t淋巴细胞白血病治疗中的应用 |
Non-Patent Citations (2)
Title |
---|
CHIA-WEI LI1 等: "Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity", 《NAT.COMMUN》 * |
CHRISTINA M. MAHER 等: "Small-molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1", 《MOL CANCER RES.》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020192770A1 (zh) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Antony et al. | Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody | |
UA120264C2 (uk) | Сполука для застосування в способі лікування імунодефіциту сd4-т клітин у суб'єкта | |
CN109112097A (zh) | 重编程癌细胞 | |
CN114686461B (zh) | 去泛素化酶usp45在制备治疗肺鳞癌药物中的应用 | |
Sheng et al. | PAR-2 promotes invasion and migration of esophageal cancer cells by activating MEK/ERK and PI3K/Akt signaling pathway | |
WO2010140694A1 (ja) | アミロイドベータペプチドの産生を促進する因子を用いた阻害剤のスクリーニング方法及びそれによって得られる阻害剤 | |
EP1301795B1 (en) | Method of identifying and/or isolating stem cells | |
EP2876160A1 (en) | Differentiation marker for and differentiation control for ocular cells | |
JP2015173601A (ja) | がん幹細胞の増殖抑制物質のスクリーニング方法 | |
Lee et al. | Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma | |
CN111751545A (zh) | 一种筛选pd-l1/pd-1检测点抑制剂的方法 | |
CN116178302B (zh) | 一种cd47蛋白泛素化修饰激动剂及其应用 | |
CN114668846B (zh) | 去泛素化酶usp45在制备治疗食管癌药物中的应用 | |
CN103800919B (zh) | Tuft1在制备肝癌诊断和治疗制剂中的应用 | |
CN105566495A (zh) | 一种特异性抑制连接蛋白26的全人抗体 | |
CN114672460B (zh) | 一种靶向cd44的异质型cic细胞模型的制备方法及应用 | |
CN116003622A (zh) | 一种用于卵巢癌治疗的嵌合抗原受体及其应用 | |
WO2006118328A1 (ja) | 脱顆粒抑制剤 | |
EP3922646A1 (en) | Detection of malignant tumor cells antibodies and uses thereof | |
US20210309729A1 (en) | Netrin g1 as a biomarker for enhancing tumor treatment efficacy | |
WO2019031781A2 (ko) | 효모 이중 혼성 스크리닝을 위한 벡터 라이브러리 및 이를 이용한 표적 단백질에 결합하는 탈유비퀴틴화 효소의 동정방법 | |
KR102527911B1 (ko) | 조절 t 세포의 약물 스크리닝 용도 | |
CN116064527B (zh) | 抑制ABCB6基因表达的siRNA及其应用 | |
KR102478897B1 (ko) | T세포 및 마크로파지를 이용한 항암제 효능 평가 방법 | |
CN114075548B (zh) | 一种靶向axl的car-t细胞及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201009 |
|
WD01 | Invention patent application deemed withdrawn after publication |